137 related articles for article (PubMed ID: 11913510)
1. E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid.
Leroi MJ; Siarakas S; Gottlieb T
Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):72-4. PubMed ID: 11913510
[No Abstract] [Full Text] [Related]
2. Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from hospitals during a 4-year period in China.
Chen YB; Gu SL; Shen P; Lv T; Fang YH; Tang LL; Li LJ
J Med Microbiol; 2018 Jan; 67(1):52-59. PubMed ID: 29160203
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility of Clostridium difficile isolates in Israel.
Tkhawkho L; Nitzan O; Pastukh N; Brodsky D; Jackson K; Peretz A
J Glob Antimicrob Resist; 2017 Sep; 10():161-164. PubMed ID: 28729205
[TBL] [Abstract][Full Text] [Related]
4. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
Rodríguez JC; Ruiz M; López M; Royo G
Int J Antimicrob Agents; 2002 Dec; 20(6):464-7. PubMed ID: 12458143
[TBL] [Abstract][Full Text] [Related]
6. Highly antibiotic-resistant Clostridium difficile isolates from Iranian patients.
Baghani A; Ghourchian S; Aliramezani A; Yaseri M; Mesdaghinia A; Douraghi M
J Appl Microbiol; 2018 Nov; 125(5):1518-1525. PubMed ID: 29957893
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators.
Freeman J; Vernon J; Vickers R; Wilcox MH
Antimicrob Agents Chemother; 2016 Jan; 60(1):689-92. PubMed ID: 26552981
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.
Rodriguez Díaz JC; López M; Ruiz M; Royo G
Int J Antimicrob Agents; 2003 Jun; 21(6):585-8. PubMed ID: 12791475
[TBL] [Abstract][Full Text] [Related]
9. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
Harper T; Miller D; Flynn HW
Ophthalmology; 2007 May; 114(5):871-5. PubMed ID: 17383732
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model.
Baines SD; Noel AR; Huscroft GS; Todhunter SL; O'Connor R; Hobbs JK; Freeman J; Lovering AM; Wilcox MH
J Antimicrob Chemother; 2011 Jul; 66(7):1537-46. PubMed ID: 21504940
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection.
Chilton CH; Crowther GS; Baines SD; Todhunter SL; Freeman J; Locher HH; Athanasiou A; Wilcox MH
J Antimicrob Chemother; 2014 Mar; 69(3):697-705. PubMed ID: 24128668
[TBL] [Abstract][Full Text] [Related]
12. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC
J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926
[TBL] [Abstract][Full Text] [Related]
13. [Epidemiological study of Clostridium difficile strains isolated in Jean-Verdier-René-Muret hospitals from 2001 to 2007].
Poilane I; Fantinato C; Cruaud P; Collignon A
Pathol Biol (Paris); 2008; 56(7-8):412-6. PubMed ID: 18842360
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization and antimicrobial susceptibilities of Clostridium difficile clinical isolates from Victoria, Australia.
Mackin KE; Elliott B; Kotsanas D; Howden BP; Carter GP; Korman TM; Riley TV; Rood JI; Jenkin GA; Lyras D
Anaerobe; 2015 Aug; 34():80-3. PubMed ID: 25944720
[TBL] [Abstract][Full Text] [Related]
15.
Freeman J; Pilling S; Vernon J; Wilcox MH
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993853
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.
Gerding DN; Hecht DW; Louie T; Nord CE; Talbot GH; Cornely OA; Buitrago M; Best E; Sambol S; Osmolski JR; Kracker H; Locher HH; Charef P; Wilcox M
J Antimicrob Chemother; 2016 Jan; 71(1):213-9. PubMed ID: 26433782
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of linezolid against Clostridium difficile.
Peláez T; Alonso R; Pérez C; Alcalá L; Cuevas O; Bouza E
Antimicrob Agents Chemother; 2002 May; 46(5):1617-8. PubMed ID: 11959617
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile.
Odenholt I; Walder M; Wullt M
Chemotherapy; 2007; 53(4):267-74. PubMed ID: 17595541
[TBL] [Abstract][Full Text] [Related]
20. The emergence of metronidazole and vancomycin reduced susceptibility in Clostridium difficile isolates in Iran.
Kouhsari E; Douraghi M; Krutova M; Fakhre Yaseri H; Talebi M; Baseri Z; Moqarabzadeh V; Sholeh M; Amirmozafari N
J Glob Antimicrob Resist; 2019 Sep; 18():28-33. PubMed ID: 30703583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
